In-House
| Project/Compound | Submission Status | Current Phase | News Update |
|---|---|---|---|
| GP2411 (denosumab) |
In Phase III | Phase III | |
| SOK583A1 (aflibercept) | In Phase III | Phase III |
First patient enrolled June 2021 |
Collaborations
Bio-Thera Solutions, Ltd.: Sandoz entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for the proposed biosimilar bevacizumab (BAT1706). Bio-Thera Solutions, Ltd. will maintain responsibility for development and manufacturing, Sandoz will have the right to commercialize the medicine upon approval in the US, Europe, Canada and selected other countries.
Polpharma Biologics: Sandoz entered into a global commercialization agreement for a proposed natalizumab biosimilar with Polpharma Biologics to commercialize and distribute the medicine in all markets upon approval, through an exclusive global license. Under the agreement, Polpharma Biologics will maintain responsibilities for the development of the drug substance. The medicine has been accepted for regulatory review by both the EMA and US FDA.
EirGenix: The agreement between Sandoz and EirGenix, Inc, a biotechnology manufacturing and development company that aspires to provide high-quality medicines for individuals and society, aims to bring to market a proposed biosimilar trastuzumab.
Gan & Lee: Under our supply and commercialization partnership with Gan & Lee, a leading insulin supplier headquartered in China with more than 20 years of experience in insulins, we are aiming to bring to market biosimilar versions of glargine, lispro and aspart insulins.
Biocon: Sandoz is in a global partnership with Asia’s premier biopharmaceuticals company in the area of immunology.